pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Wegovy · news · pharmadog
← back to Wegovy
News mentioning Wegovy
133
stories
3d
Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
biospace
4d
3 takeaways from a European obesity scientific meeting
biopharma dive
4d
Fresenius Kabi manufacturing plant hit with FDA warning letter after adverse events
biospace
4d
#EASD26: Regeneron's antibody helps patients regain muscle after stopping GLP-1 therapy
endpoints
5d
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
fiercebiotech
5d
Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3
biospace
5d
#EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes
endpoints
5d
Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
biospace
5d
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
fiercebiotech
6d
Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill
biopharma dive
6d
Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal
biospace
7d
Roche drops muscle-sparing obesity antibody after flunked interim analysis
fiercebiotech
7d
STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’
stat
10d
This week in charts: Novo’s rise and fall and AI biotechs’ big haul
biopharma dive
11d
FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’
biospace
12d
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
biospace
13d
Viking shares surge on updated obesity drug data
biopharma dive
13d
Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030
biospace
13d
Novo’s workforce reduction climbs to 13,000 to fuel R&D work
biospace
13d
Siemens Healthineers and Novo team up on fatty liver disease awareness, testing
fiercebiotech
14d
Novo talks up drug launches in effort to win back investors
biopharma dive
14d
Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
biospace
14d
Novo buys three early-stage obesity assets from Kallyope as investor pressure mounts
biospace
14d
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
fiercebiotech
14d
Are healthcare systems really ready for GLP-1s?
biopharma dive
17d
Artelo’s ex-AstraZeneca cannabinoid agonist holds its own against GLP-1 drug semaglutide in obese mice
fiercebiotech
17d
Refreshed Novo corrals 3 new early-stage obesity drugs from Kallyope
fiercebiotech
18d
Novo partners with Orbis, deepening investment in oral peptide drugs
biopharma dive
18d
Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs
biospace
19d
'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrand
fiercebiotech
← prev
page 1 of 5
next →
